25
Participants
Start Date
March 18, 2024
Primary Completion Date
October 17, 2024
Study Completion Date
October 17, 2024
STSP-0601 for Injection
A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
Shengjing Hospital Affiliated to China Medical University, Shenyang
The first hospital of Jilin University, Changchun
Harbin First Hospital Hematology Tumor Research Center, Harbin
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Nanjing University School of Medicine Affiliated Gulou Hospital, Nanjing
Anhui Provincial Hospital, Hefei
Affiliated Hospital of Qingdao University, Qingdao
Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin
The First Affiliated Hospital of Nanchang University, Nanchang
Fujian Medical University Affiliated Union Medical College Hospital, Fuzhou
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
Xiangya Hospital of Central South University, Changsha
Henan Cancer Hospital, Zhengzhou
Southern Medical University Southern Hospital, Guangzhou
Shenzhen Second People's Hospital, Shenzhen
Guizhou Medical University Affiliated Hospital, Guiyang
West China Hospital of Sichuan University, Chengdu
The Second Affiliated Hospital of Kunming Medical University, Kunming
Xi'an Central Hospital, Xi’an
Lanzhou University First Hospital, Lanzhou
Staidson (Beijing) Biopharmaceuticals Co., Ltd
INDUSTRY